Keyphrases
Acute Myeloid Leukemia
28%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
32%
Bone Marrow Involvement
14%
Chemoimmunotherapy
15%
Chemotherapy
28%
Chimeric Antigen Receptor T Cells (CAR-T)
28%
Clinical High Risk
14%
Complete Response
19%
COVID-19
28%
Cytarabine
21%
Cytogenetic Risk
14%
Cytomegalovirus
14%
Diffuse Large B-cell Lymphoma (DLBCL)
69%
Disease Progression
16%
Elderly Patients
100%
Fear of COVID-19
14%
Follicular Lymphoma
32%
High Risk
16%
High-dose Methotrexate (HD-MTX)
42%
Hodgkin
28%
Hodgkin Lymphoma
38%
Interim PET-CT
14%
Israeli
22%
Lymphoma Patients
75%
Marijuana
14%
Median Progression-free Survival
14%
Medical Center
22%
Occult
14%
Oncological Treatment
19%
Oncology Patients
19%
Overall Survival
50%
Partial Response
22%
Patient Experience
14%
Polatuzumab
23%
Positron Emission Tomography-computed Tomography (PET-CT)
32%
Predictive Value
14%
Primary Central Nervous System Lymphoma (PCNSL)
28%
Progression-free Survival
37%
Radiotherapy
21%
Refractory Diffuse Large B-cell Lymphoma
25%
Relapsed or Refractory
35%
Retrospective Analysis
42%
Rituximab
30%
Single Center
28%
Splenomegaly
15%
Tel Aviv
17%
Thrombocytopenia
17%
Treatment Adherence
14%
Working Diagnosis
28%
Young Patients
24%
Medicine and Dentistry
Aggressive Lymphoma
14%
B Cell
16%
Bone Mass
14%
Breast Cancer Screening
14%
Cannabis Use
14%
CD20
14%
Cell Transplantation
14%
Central Nervous System Disease
14%
Chemoimmunotherapy
16%
Chimeric Antigen Receptor
14%
Chimeric Antigen Receptor T-Cell
28%
Chimeric Antigen Receptor T-Cell Immunotherapy
14%
Cohort Analysis
28%
Computer Assisted Tomography
14%
COVID-19
28%
Cytomegalovirus
14%
Diffuse Large B-Cell Lymphoma
64%
Disease
38%
Drug Megadose
21%
Elderly Patient
35%
Follicular Lymphoma
31%
Gastrointestinal Tract
14%
Hairy Cell Leukemia
14%
Hematologic Malignancy
14%
Hematopoietic Stem Cell
14%
Hodgkin's Lymphoma
38%
Infection
20%
Intestine
14%
Janus Kinase 2
14%
Lymphoproliferative Disease
17%
Mantle Cell Lymphoma
14%
Medical Cannabis
14%
Methotrexate
28%
Myeloproliferative Neoplasm
14%
Overall Survival
37%
Patient Experience
14%
Patient with Inflammatory Bowel Disease
14%
Personal Experience
14%
Phlebothrombosis
14%
Polatuzumab Vedotin
14%
Positron Emission Tomography
28%
Positron Emission Tomography-Computed Tomography
31%
Progression Free Survival
30%
Prospective Study
14%
Radiation Therapy
21%
Rituximab
17%
Splenectomy
14%
Splenomegaly
17%
Symptom
14%
Thrombocytopenia
14%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
14%
Adverse Event
16%
Anticarcinogen
14%
B Cell Lymphoma
14%
Cannabis
11%
Carmustine
14%
Cefepime
14%
Chemotherapy
56%
Chimeric Antigen Receptor
14%
Chronic Lymphatic Leukemia
14%
Clinical Feature
7%
Combination Therapy
10%
Coronavirinae
14%
Cyclophosphamide
14%
Cytarabine
17%
Cytomegalovirus
14%
Diffuse Large B Cell Lymphoma
40%
Disease
36%
Disease Course
11%
Disease Exacerbation
16%
Etoposide
7%
Gemtuzumab Ozogamicin
14%
Hairy Cell Leukemia
14%
Hematologic Malignancy
14%
Hodgkin Disease
28%
Ibrutinib
14%
Immune Dysregulation
14%
Immunoglobulin A
7%
Immunoglobulin Antibody
7%
Infection
43%
Infectious Complication
7%
Malignant Neoplasm
7%
Medical Cannabis
14%
Metastatic Colorectal Cancer
14%
Methotrexate
28%
Mucosa Inflammation
7%
Neoplasm
7%
Overall Survival
50%
Polatuzumab Vedotin
14%
Primary Central Nervous System Lymphoma
20%
Progression Free Survival
38%
Prospective Study
16%
Remdesivir
9%
Remission
24%
Retrospective Study
10%
Rituximab
23%
Splenomegaly
16%
Symptom
6%
Thiotepa
14%
Thrombocytopenia
16%